Company Will Explore Diagnostic and Imaging Utility after Further Characterization
Another Development Milestone Achieved
HASSELT, Belgium | September 29, 2009 | MabCure, Inc. (“MabCure”), a biotechnology company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has reached another development milestone, with the creation of its MAbs against Colorectal Cancer (CRC). After further characterization the company plans to explore the utility of these MAbs in terms of both the early diagnosis of CRC (in blood or feces specimens), as well as imaging agents for detecting micrometastatic disease during surgery and the detection of cancerous polyps during colonoscopy.
“Colorectal Cancer (CRC) is a devastating disease that could be treated effectively if diagnosed at an early stage,” said Dr. Amnon Gonenne, MabCure’s President and CEO.
“Creating MAbs against CRC allows MabCure to explore its uses for diagnosis and imaging, producing tremendous value for our company and shareholders, complementing the work we are doing in ovarian and prostate cancers. Today’s announcement is consistent with our focus on commercializing diagnostic tests in markets in which there is significant demand.”
All men and women fifty years and older should be screened for CRC, a leading cause of death for both sexes in nearly equal numbers. The company estimates the European and U.S. market potential to each be in the billion dollar range.
For more news and information on MabCure Inc., please visit www.IRGnews.com/coi/MBCI where you can find the CEO’s video, a fact sheet on the company, investor presentations, and more.
About MabCure Inc.
MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which will be developed as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure initial goal is to develop its novel MAbs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the Company’s website www.mabcure.com.
SOURCE: MabCure Inc.
Post Views: 91
Company Will Explore Diagnostic and Imaging Utility after Further Characterization
Another Development Milestone Achieved
HASSELT, Belgium | September 29, 2009 | MabCure, Inc. (“MabCure”), a biotechnology company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has reached another development milestone, with the creation of its MAbs against Colorectal Cancer (CRC). After further characterization the company plans to explore the utility of these MAbs in terms of both the early diagnosis of CRC (in blood or feces specimens), as well as imaging agents for detecting micrometastatic disease during surgery and the detection of cancerous polyps during colonoscopy.
“Colorectal Cancer (CRC) is a devastating disease that could be treated effectively if diagnosed at an early stage,” said Dr. Amnon Gonenne, MabCure’s President and CEO.
“Creating MAbs against CRC allows MabCure to explore its uses for diagnosis and imaging, producing tremendous value for our company and shareholders, complementing the work we are doing in ovarian and prostate cancers. Today’s announcement is consistent with our focus on commercializing diagnostic tests in markets in which there is significant demand.”
All men and women fifty years and older should be screened for CRC, a leading cause of death for both sexes in nearly equal numbers. The company estimates the European and U.S. market potential to each be in the billion dollar range.
For more news and information on MabCure Inc., please visit www.IRGnews.com/coi/MBCI where you can find the CEO’s video, a fact sheet on the company, investor presentations, and more.
About MabCure Inc.
MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which will be developed as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure initial goal is to develop its novel MAbs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the Company’s website www.mabcure.com.
SOURCE: MabCure Inc.
Post Views: 91
